Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Eight-Week Randomised, Double-Blind Study to Compare the Fixed-Dose Combination of Telmisartan 40mg + Amlodipine 10mg Versus Telmisartan 80mg + Amlodipine 10mg Versus Amlodipine 10mg Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Amlodipine 10mg Monotherapy.

Next Previous
Trial Profile

An Eight-Week Randomised, Double-Blind Study to Compare the Fixed-Dose Combination of Telmisartan 40mg + Amlodipine 10mg Versus Telmisartan 80mg + Amlodipine 10mg Versus Amlodipine 10mg Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Amlodipine 10mg Monotherapy.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amlodipine/telmisartan (Primary) ; Amlodipine
  • Indications Essential hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms TEAMSTA-10

Most Recent Events

  • 23 Jun 2012 Planned number of patients changed from 756 to 2530 as reported by European Clinical Trials Database.
  • 13 Oct 2010 A Boehringer Ingelheim media release states the EMEA has approved telmisartan/amlodipine for the treatment of hypertension in adults.
  • 26 Jul 2010 European Committee for Medicinal Products for Human Use (CHMP) adopted a Positive Opinion for the approval of TWYNSTA based on the results of this trial and TEAMSTA-5 and TEAMSTA Severe HTN, according to a Boehringer-Ingelheim media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top